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Abstract
Introduction: To evaluate the usefulness of measuring maternal anti-TSH receptor antibodies (TRAbs) and foetal ultrasound (US) monitor-
ing in cases of current or past maternal hyperthyroidism.
Material and methods: 77 pregnant women suffering from hyperthyroidism or with a history of Graves’ hyperthyroidism were observed 
prospectively. Maternal serum TSH, fT4, fT3, TRAbs, and foetal US were performed at baseline and repeated every 2–4 weeks when 
needed. Neonatal thyroid status was assessed based on serum TSH, fT4 and fT3 obtained in the first days of life.
Results: 35 women were diagnosed with gestational hyperthyroidism and 42 with Graves’ disease; among them 26 had current and 
16 past hyperthyroidism. Foetal and neonatal thyroid dysfunction occurred only in cases of maternal Graves’ disease: nine (21%) and 
three (7%), respectively. Active maternal Graves’ hyperthyroidism and TRAbs elevated at least five times above the upper normal limit 
predisposed to foetal hyperthyroidism. Maternal anti-thyroid drug therapy (ATD) and low TRAbs and fT4 were the risk factors of foetal 
hypothyroidism. Abnormal foetal thyroid sonogram was the only sign of foetal thyroid dysfunction. Four patients (9.5%) had high TRAbs 
in the 3rd trimester (10.8–29.9 IU/mL), but neither foetal nor neonatal thyroid dysfunctions were noted.
Conclusions: In the cases of maternal Graves’ disease, foetal thyroid dysfunction occurs more often than commonly assumed. 
Foetal thyroid US is a valuable tool in early diagnosis and monitoring of the foetal thyroid status in pregnancy complicated by ma-
ternal Graves’ disease. The evaluation of biological activity of maternal TRAbs may be helpful in prenatal diagnosis in some cases. 
(Endokrynol Pol 2014; 65 (4): 259–268)
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Streszczenie
Wstęp: Ocena przydatności oznaczania matczynych przeciwciał przeciwko receptorowi TSH (TRAb) i ultrasonograficznego (US) moni-
torowania płodu u ciężarnej z aktywną lub przebytą nadczynnością tarczycy
Materiał i metody: 77 ciężarnych z aktualną nadczynnością tarczycy lub chorobą Gravesa i Basedowa (MGB) w wywiadach było obser-
wowanych prospektywnie. Oceniano matczyne stężenie TSH, fT4, fT3, TRAb oraz US płodu wstępnie oraz co 2–4 tygodnie w zależności 
od potrzeb. U noworodka badano TSH, fT4, fT3 w pierwszych dniach życia. 
Wyniki: U 35 badanych rozpoznano tyreotoksykozę ciężarnych a u 42 MGB: wśród nich 26 miało aktualną a 16 przebytą nadczynność 
tarczycy. Płodowa i noworodkowa dysfunkcja tarczycy występowała wyłącznie w przypadkach matczynej MGB: odpowiednio u 9 (21%) 
i 3 (7%) dzieci. Matczyna aktywna nadczynność tarczycy i podwyższone przynajmniej 5-krotnie TRAb predysponowały do nadczynności 
tarczycy u dziecka. Leczenie tyreostatyczne matki, niskie stężenie TRAb i fT4 były czynnikami ryzyka dziecięcej hipotyreozy. Nieprawi-
dłowy obraz US tarczycy u dziecka był jedynym objawem płodowej dysfunkcji tarczycy. W 4 przypadkach (9,5%) wysokich TRAb u matki 
(10,8–29,9 IU/mL) stwierdzanych w III trymestrze ciąży nie obserwowano zaburzeń czynności tarczycy u dziecka. 
Wnioski: W przypadku ciąży u kobiety z MGB płodowe zaburzenia czynności tarczycy występują częściej niż się powszechnie 
przyjmuje. Monitorowanie ultrasonograficzne tarczycy płodu jest czułą i wartościową metodą oceny stanu czynnościowego tarczycy 
u dziecka. Ocena biologicznej aktywności matczynych TRAb może być przydatna w niektórych przypadkach diagnostyki prenatalnej. 
(Endokrynol Pol 2014; 65 (4): 259–268)
Słowa kluczowe: matczyna choroba Gravesa i Basedowa; ciąża; TRAb; ultrasonografia płodu
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Introduction
The impact of maternal thyroid status during preg-
nancy on the development of progeny has been studied 
extensively [1–6]. Both maternal hyper- and hypothy-
roidism can impair somatic and especially neurological 
status of the offspring [7–18]. Even isolated maternal 
hypothyroxinemia with free thyroxin (fT4) values below 
the 5th–10th percentiles and normal TSH concentrations 
during the first half of gestation have been reported to 
be a risk factor for cognitive and motor delay in early 
childhood [19–24]. Maternal Graves’ disease, affecting 
0.1–0.4% of pregnancies, and anti-thyroid drug (ATD) 
therapy during gestation, pose a great therapeutic chal-
lenge. Maternal thyroid stimulating antibodies (TSAbs) 
that freely cross the placenta can overstimulate foetal 
thyroid after the 20th week of gestation (WG), when foe-
tal TSH receptors become responsive to TSH and TSH 
receptor antibodies. On the other hand, transplacental 
passage of ATD, which influences foetal thyroid much 
more than the maternal gland, can cause foetal hypo-
thyroidism. The progress in prenatal ultrasonography 
(US) enabled early diagnosis of foetal thyroid dysfunc-
tion without the need to perform invasive procedures 
such as foetal blood sampling. The symptoms of foetal 
hyperthyroidism that can be registered ultrasono-
graphically include goitre, tachycardia, cardiomegaly, 
hydrops, advanced bone maturation, craniosyntosto-
sis, and growth retardation. Foetal hypothyroidism 
can manifest with goitre, bradycardia, delayed bone 
maturation, and growth retardation. Foetal goitre can 
be a cause of foetal head hyperextension, respiratory 
and swallowing obstruction, and polyhydramnios [25, 
26]. According to all current guidelines [25–28], foetal 
US monitoring should be performed after the 18th–22nd 
weeks of gestation (WG) in case of either ATD therapy 
or maternal Graves’ disease with elevated TSH receptor 
antibodies (TRAb), irrespective of whether hyperthy-
roidism is active or ablative therapy has been carried 
out. Cordocentesis should be restricted to cases of 
confounding clinical data, when laboratory results can 
influence therapy, especially when an intra-amniotic 
thyroxin injection is considered. The aim of our study 
was to investigate the usefulness of maternal TRAb 
measurements and foetal US monitoring in maternal 
hyperthyroidism or previous history of Graves’ disease. 
We also intended to verify the previously established 
foetal thyroid nomograms for the Polish population.
Material and methods
A prospective study of pregnant women with current 
hyperthyroidism, irrespective of its cause or history of 
Graves’ disease, was conducted between 2009 and 2012. 
Patients were referred to the outpatient endocrinology 
department of Bielański Hospital in Warsaw by either 
their obstetricians or endocrinologists. Seventy seven 
pregnant women at the 6th–38th WG were enrolled into 
the study.
Graves’ disease was diagnosed based on the 
patients’ history and previous medical reports, and 
presence of diffuse hypervascular goitre, orbitopathy, 
dermopathy, and elevated serum TRAb concentration 
observed at least once. Gestational hyperthyroidism 
was diagnosed when the clinical symptoms of Graves’ 
disease were absent and serum TRAbs were negative. 
Diagnosis of toxic nodular goiter was established when 
thyroid nodules with increased central or peripheral 
blood flow were visualised on power-Doppler exami-
nation, no clinical symptoms of Graves’ disease were 
found, serum TRAbs were negative, and hyperthy-
roidism continued throughout the gestation and after 
delivery. The assessment of thyroid status was based on 
clinical and laboratory data. ATD therapy was provided 
according to the current guidelines [25–28]; until the 
end of 2011, propylthiouracil (PTU) was preferred over 
methimazole (MMI) in order to avoid MMI embryopa-
thy. Since 2012, PTU use has been limited to the first 
trimester due to its potential hepatotoxicity, and MMI 
has been implemented. Baseline values of serum thy-
rotropin (TSH), free T3 (fT3), free T4 (fT4), thyroid-per-
oxidase antibodies (TPOAbs), thyroglobulin antibodies 
(TGAbs) and TRAb concentration were determined in 
each patient, and thyroid US was performed. Subse-
quently, the TSH, fT4 and fT3 tests were repeated every 
2–4 weeks. In patients with Graves’ disease, serum 
TRAbs were additionally determined after the 20th WG 
and repeated monthly several times. Baseline foetal US 
was carried out in each case. In pregnant women with 
elevated TRAbs or treated with ATD, foetal US was 
repeated every 2–4 weeks, starting at the 20th WG. In 
other cases, routine US examinations were performed 
in the 18th–23rd and the 30th–33rd WG. Foetal sonograms 
were obtained using an Accuvix XQ Medison scanner 
with an abdominal convex 3–7 MHz transducer. An 
evaluation of gestational age, amniotic fluid volume, 
foetal anatomy, growth parameters, viability, thyroid 
size, heart rate, and bone maturation was carried out. 
Foetal thyroid diameter, circumference, and area were 
measured via transverse axial view through the foetal 
neck as described earlier [29, 30]; the results were com-
pared with the reference values for the Polish popula-
tion [31]. Foetal thyroid measurements above the 95th 
percentile were indicative of foetal goitre. In line with 
previous reports, colour Doppler ultrasonography was 
also used to assess foetal thyroid vascularisation [32, 33].
In evaluating foetal bone maturation, the distal 
femoral epiphysis ossification centre was assessed: its 
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presence before the 31st WG was indicative of acceler-
ated bone maturation due to foetal hyperthyroidism, 
and its absence after the 33rd WG was characteristic of 
delayed bone maturation resulting from foetal hypothy-
roidism [34, 35]. Foetal tachycardia was defined as foetal 
heart rate over 160 beats/min and foetal bradycardia 
as foetal heart rate below 120 beats/min. In two cases, 
foetal blood sampling was performed in an attempt to 
measure foetal TSH, fT4, and fT3 concentrations.
To evaluate neonatal thyroid status, TSH re-
sults from dried-spot tests, performed after the first 
48 hours of life, were obtained in each case. In the cases 
of elevated maternal TRAbs, ATD treatment or foetal 
US signs of abnormal thyroid function, TSH, fT4 and 
fT3 concentrations were determined after delivery in 
cord blood or between the 1st and 3rd days of life, and 
several times thereafter.
Quantitative analyses of TSH, fT3, fT4, TPOAbs, and 
TGAbs were performed by chemiluminescent immuno-
assays (EURO/DPC, United Kingdom), using an Immu-
lite 2000 automatic analyser. TRAbs were determined 
by the competitive electrochemiluminescent method, 
using soluble porcine TSH receptor and human mono-
clonal TSH receptor stimulating antibody, M22 (Roche 
Diagnostics GmbH, Mannheim, Germany). An Elecsys 
2010 analyser was used to determine serum TRAbs. 
Reference ranges for the analysed parameters were as 
follows: TSH 0.4–4.0 mIU/mL, fT4 10.4–24.4 pmol/L, 
fT3 1.8–4.2 pg/mL, TPOAbs < 35 IU/mL, TGAbs < 40 IU/mL, 
TRAbs < 1.8 IU/mL. Normal foetal values for TSH, 
fT4, fT3, according to gestational age, were described 
by Hume and Guibourdenche [36, 37]. Neonatal TSH 
values for the Polish population, obtained in dried-
spot tests, were as follows: median TSH concentration 
1.45 mIU/L, 23.5% TSH results ≤ 0.5 mIU/L, 95% TSH 
results ≤ 5 mIU/L, and 0.2% abnormal measurements 
> 12.0 mIU/L [38]. In our study, the obtained neonatal 
TSH results in dried-spot tests were compared to the 
control group, consisting of 68 neonates born to mothers 
with normal thyroid function [39].
The t-Student test was used to compare parametric 
data and chi-squared test to compare non-parametric 
data on statistical analysis. Neonatal TSH distributions 
obtained in dried-spot tests were compared using 
a non-parametric Mann-Whitney test. P < 0.05 was 
considered significant.
This study was approved by the Ethics Committee of 
the Medical Centre of Postgraduate Education, and in-
formed consent was obtained from all the participants.
Results
The mean age of the studied group of 77 pregnant 
women was 30.9 years (range: 22–38). Sixty one patients 
presented with hyperthyroidism: gestational hyperthy-
roidism (n = 35) or Graves’ disease (n = 26). There were 
no cases of toxic nodular goitre. Sixteen patients had 
a history of hyperthyroidism due to Graves’ disease. 
The baseline characteristics of the group are presented 
in Figure 1.
Patients with gestational hyperthyroidism
In 35 pregnant women with gestational hyper-
thyroidism, suppressed serum TSH concentration 
(< 0.1 mIU/L) was observed between the 6th and 38th 
WG (mean 20 ± 8.3 WG). Additionally, 19 patients 
(54%) had elevated serum fT3 or fT4 concentrations. 
In 12 of them, short-term ATD therapy was prescribed 
due to concomitant hyperemesis gravidarum or un-
clear underlying cause of hyperthyroidism (Table I). 
Hyperthyroidism was recurrent in three patients: 
two of them had previous episodes of gestational 
thyrotoxicosis, and one a history of silent thyroiditis. 
In the postpartum period, hyperthyroidism occurred 
in three women with elevated TPOAb during preg-
nancy: postpartum thyroiditis was recognised in two 
cases, and one patient developed Graves’ disease with 
severe hyperthyroidism and elevated serum TRAbs 
(40 IU/mL). This patient had been treated with ATD 
for one year and radioiodine therapy was instituted 
after lactation was completed.
Patients with Graves’ disease
Graves’ disease was diagnosed in 26 pregnant women 
with current hyperthyroidism and in 16 patients with 
previous episodes of hyperthyroidism (Table II).
As many as 21 out of 26 patients with current hy-
perthyroidism (81%) experienced the first episode of 
the disease, while the other five (19%) had recurrent 
hyperthyroidism. Sixteen women (61.5%) became preg-
nant while on ATD treatment (duration 2–36 months, 
mean 13.6 months). In ten out of 26 cases (38%) remis-
sion of hyperthyroidism was achieved in the 2nd and 
3rd trimester, and ATD treatment was withdrawn. Eight 
patients from the group with remission had low serum 
TRAb levels: 0.2–2.2 IU/mL (mean 0.78 ± 0.6 IU/mL). 
Serum TRAb levels remained high (15.2 IU/mL and 
26.2 IU/mL) in the other two cases of hyperthyroidism 
remission; one of these patients was treated with 131-I 
before pregnancy.
One patient (T.K., gravida 3, para 2) underwent 
thyroidectomy during gestation. Her hyperthy-
roidism exacerbated severely (fT3 30 pg/mL, fT4 
39.5 pmol/L) in the 1st trimester. The goitre volume was 
nearly 80 mL; the patient needed high ATD doses to 
control hyperthyroidism and was not compliant with 
therapy. Total thyroidectomy was performed during 
the 2nd trimester; the surgery was complicated with 
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Table II. Characteristics of 42 pregnant women with Graves’ disease and current or past hyperthyroidism
Tabela II. Charakterystyka 42 kobiet ciężarnych z aktywną lub przebytą nadczynnością tarczycy w przebiegu choroby Gravesa 
i Basedowa
Characteristic Graves’ hyperthyroidism p
Current n = 26    
n (%)
Past n = 16 
n (%)
Previous history of hyperthyroidism 5/26 (19) 16/16 (100) 
Twin pregnancy  0  0
Hyperemesis gravidarum  0  0
↑TRAb 11/26 (42)  5/16 (31)  NS
 Serum TRAb mean ± SD,
range [IU/mL]
 7.01 ± 11.21
0.2-40
 3.09 ± 8.07
0.2- 40
 NS
↑TPOAb or ↑TGAb  19/26 (73)  8/16 (50)  NS
Abnormal thyroid US
Nodularity
Hypoechogenicity
Increased blood flow in thyroid parenchyma
 24/26 (92)
8/26 (31)
21/26 (81)
23/26 (88)
 16/16 (100)
4/16 (25)
9/16 (55)
6/16 (37.5)
 NS
NS
NS
0.001
ATD when became pregnant  16/26 (61.5)  0/16  
L-T4 when became pregnant  0/26  15/16 (87.5)  
Previous surgery  0/26  4/16 (25)  0.03
Previous 131-I  3/26 (11.5)  10/16 (62.5)  0.001
hypoparathyroidism. The patient was treated with 
L-thyroxin, alphacalcidol and calcium carbonate, and 
normal ranges of serum TSH, fT4 and calcium were 
maintained. Serum TRAb concentrations decreased 
from 30 IU/mL in the 2nd trimester to 10.8 IU/mL after 
surgery. There were no signs of foetal thyroid dysfunc-
tion on US monitoring. The only abnormal US finding 
was SGA (small for gestational age), which was prob-
ably related to maternal smoking. The patient had 
a normal labour and delivered a healthy male neonate 
weighing 2,210 g and with an Apgar score of 9. The 
newborn’s TSH concentration determined on dried-
spot test was 1.98 mIU/mL; also the measurements 
taken one month later were normal (TSH 6.8 mIU/mL, 
fT4 20.2 pmol/L, fT3 2.78 pg/mL).
One case of hyperthyroidism recurrence was 
documented during observation in the group of 
16 pregnant women with a history of hyperthyroid-
ism due to Graves’ disease. Patient A.S. (gravida 2, 
para1), who had undergone subtotal thyroidectomy 
11 years earlier, was on L-thyroxin therapy from 
the time of surgery to the 3rd trimester. At the 35th 
WG, L-thyroxin was withdrawn due to TSH sup-
pression. Two weeks later, maternal measurements 
Table I. Characteristics of 35 pregnant women with 
gestational hyperthyroidism
Tabela I .  Charakter ystyka 35 kobiet  ciężar nych 
z tyreotoksykozą ciężarnych
Characteristic N (%)
Previous history of hyperthyroidism
Twin pregnancy
Hyperemesis gravidarum
↑TPOAb or ↑TGAb
Abnormal thyroid US
— Nodularity
— Hypoechogenicity
— Increased blood flow in thyroid parenchyma
3/35 (8.5)
5/35 (14)
10/35 (28)
6/33 (18)
20/34 (58)
11/34 (32)
4/34 (12)
5/34 (14)
Figure 1. Baseline characteristics of 77 pregnant women with 
current or past hyperthyroidism
Rycina 1. Wstępna charakterystyka 77 kobiet ciężarnych 
z aktywną lub przebytą nadczynnością tarczycy
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were indicative of mild thyrotoxicosis and serum 
TRAb level was > 40 IU/mL. Foetal US revealed 
a goitre with increased central blood flow. Foetal 
hyperthyroidism was diagnosed, and the mother 
was treated with methimazole (10 mg daily). After 
delivery, hyperthyroidism was diagnosed, both in 
the mother and her newborn.
Maternal current or past hyperthyroidism and 
thyroid status of the child
US foetal monitoring revealed the signs of foetal thyroid 
dysfunction in nine cases of maternal Graves’ disease 
(21%). Foetal thyroid performance was abnormal in 
each case: enlarged size and/or increased blood flow 
were documented while other signs of foetal thyroid 
dysfunction were absent. An intensive blood flow 
throughout the whole thyroid and its borderline large 
size (between the 90th and 95th percentiles) were ob-
served in two cases. Enlarged thyroid size with (n = 5) 
or without (n = 2) concomitant hypervascularisation 
was documented in the other seven cases. The US 
patterns of foetal thyroid abnormalities, according to 
estimated foetal thyroid dysfunction, are presented in 
Table III.
Foetal thyroid status was estimated based on the 
course of maternal thyroid disease, maternal fT4, fT3 
and TRAb concentrations, ATD doses, and foetal US 
monitoring. Foetal blood sampling was performed due 
to confounding clinical data in two cases; no complica-
tions related to the procedure were noted. Foetal hypo-
thyroidism and foetal hyperthyroidism were diagnosed 
in five and four cases, respectively. Maternal aspects 
presumptive for foetal hypothyroidism included ATD 
treatment, and low serum TRAb and fT4 concentra-
tions (within the lowest third of normal limit or below 
the normal range) in the 3rd trimester. Goitre without 
increased vascularisation or with increased peripheral 
blood flow represented foetal sign of hypothyroidism. 
The daily doses of ATD were rather low: 200 mg of PTU 
in one patient, and 25–50 mg of PTU in the others.
Maternal aspects presumptive for foetal hyperthy-
roidism included current hyperthyroidism and high 
serum TRAb levels in the 3rd trimester. Increased blood 
flow throughout the whole thyroid gland (central hy-
pervascularisation), hypoechogenicity, goitre or thyroid 
size in the upper normal range (between the 90th and 
95th percentiles) were foetal signs characteristic for hy-
perthyroidism. The observed maternal TRAb concentra-
tions ranged between 9.2 and > 40 IU/mL, mean 31.1 ± 
± 7.39 IU/mL (5- to 20-fold above the upper normal 
limit). Maternal fT4 and fT3 levels and ATD doses were 
quite low in two cases of foetal hyperthyroidism, prob-
ably as a result of previous radioiodine and surgical 
treatment (Table IV).
Maternal therapy was modified in each of the nine 
cases with foetal thyroid dysfunction. In cases of suspected 
foetal hypothyroidism, maternal ATD treatment was 
withdrawn or significantly diminished; a decrease in the 
foetal goitre size was observed in the majority of cases. In 
cases of suspected foetal hyperthyroidism, maternal ATD 
treatment was augmented or instituted de novo, resulting 
in the diminishment or disappearance of increased blood 
flow within foetal thyroid, and goitre size reduction. Even-
tually, maternal treatment modification was reflected by 
fewer cases of thyroid dysfunction observed in newborns 
(three out of 42 cases, 7%) (Fig. 2).
Table III. Patterns of abnormal foetal US scan in foetal hyper- and hypothyroidism
Tabela III. Patologiczne wzorce ultrasonograficzne tarczycy płodu w zależności od rodzaju dysfunkcji tarczycy 
Foetal thyroid US scan Foetal hyperthyroidism Foetal hypothyroidism
Increased central blood flow, hypoechogenicity, normal size N = 2 N = 0
Increased central blood flow, hypoechogenicity, goitre N = 2 N = 1
Increased peripheral blood flow, hypoechogenicity,
goitre
 N = 0  N = 2
Goitre without increased vascularisation  N = 0  N = 2
Table IV. Foetal thyroid dysfunction according to maternal 
data
Tabela IV. Zaburzenia czynności tarczycy płodu a parametry 
matczyne 
Maternal data Foetal 
hyperthyroidism 
n = 4
Foetal 
hypothyroidism 
n = 5
 p
PTU dose [mg/d] 
mean ± SD, range
56.25 ± 71.8 
0–150
70.0 ± 73.7 
25–200
 NS
fT4 [pmol/L] 
mean ± SD,  
range
19.20 ± 4.81 
14.8–24.6
12.43 ± 2.07 
9.2–14.46
 0.02
fT3 [pg/mL] 
mean ± SD, range
 8.65 ± 3.58 
4.7–13.4
 4.09 ± 0.89 
2.7–5.0
 0.02
TRAb [IU/mL] 
mean ± SD,  
range
  
31.12 ± 14.78 
9.2–40
  
5.32 ± 8.76 
0.2–20.9
 0.01
264
PR
A
C
E 
O
RY
G
IN
A
LN
E
Hyperthyroidism during pregnancy: maternal TRAb and foetal US monitoring  Małgorzata Gietka-Czernel et al.
One of the cases of foetal and neonatal hypothy-
roidism was observed in a woman on prolonged ATD 
therapy, with negative TRAbs, who was enrolled into 
the study at the 38th WG. Her serum TSH and fT4 were 
1.2 mIU/mL and 9.0 pmol/L, respectively. Foetal goitre 
with increased peripheral blood flow and head hyper-
extension was observed on US. ATD therapy was with-
drawn and the patient delivered via caesarean section 
at the 39th WG. Transient neonatal hypothyroidism and 
small goitre were observed at birth, but disappeared 
quickly during further follow-up. Modification of the 
maternal treatment led to delivery of healthy euthyroid 
children in the other four cases of suspected foetal 
hypothyroidism.
Among the four cases of suspected foetal hyperthy-
roidism, only one neonate was euthyroid and remained 
healthy during the next three months of follow-up. The 
other one was diagnosed with hyperthyroidism on the 
first day of life. In the other two newborns, initially 
euthyroid or hypothyroid, hyperthyroidism relapsed 
within two weeks after birth. The mothers of the three 
neonates who developed hyperthyroidism were thy-
rotoxic during pregnancy and showed highly elevated 
TRAbs in the 3rd trimester (35.5, > 40, and > 40 IU/mL).
Four patients from the group of women with 
Graves’ disease (9.5%) showed high TRAb levels 
in the 3rd trimester (range: 10.8–29.9 IU/mL, mean 
20.5 ± 4.5 IU/mL) but their children did not dem-
onstrate any thyroid dysfunction during the foetal 
and neonatal period. Two of these patients were on 
L-thyroxin treatment after surgery and 131I therapy. 
Remission of hyperthyroidism occurred in the 3rd tri-
mester in another woman, and ATD was discontinued. 
The other patient showed suppressed serum TSH and 
normal fT4 and fT3 throughout the whole gestation, 
and was not treated with ATD. The possible explana-
tion of this phenomenon is the lack of stimulating 
properties of TRAbs or the balance between stimulat-
ing and inhibiting anti-TSH receptor antibodies.
Neither foetal nor neonatal thyroid dysfunctions 
were observed in the group of patients with gesta-
tional hyperthyroidism. Neonates born to mothers with 
a history of gestational thyrotoxicosis did not differ from 
the controls in terms of TSH levels obtained in dried-spot 
tests: median TSH 1.010 mIU/mL (range: 0.01–9.7 mIU/mL) 
vs. 1.495 mIU/mL (range: 0.01–7.2 mIU/mL), P = NS. 
The comparison of the distributions of TSH levels in 
the two groups is presented on Figure 3.
Figure 2. Maternal Graves’ disease and foetal and neonatal outcomes
Rycina 2. Matczyna choroba Gravesa i Basedowa a stan czynnościowy tarczycy u płodu i noworodka
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Discussion
Maternal gestational hyperthyroidism, observed in 
35 out of 61 patients (57%), was the most common cause 
of hyperthyroidism in pregnant women included in our 
study. An important discriminant for this group was 
the frequent occurrence of hyperemesis gravidarum 
(28%) and twin pregnancy (14%); this is consistent with 
the observations of other authors [40–43]. Although 
negative signs of Graves’ disease and negative serum 
TRAbs were the main indicators for recognising ges-
tational thyrotoxicosis, the diagnosis turned out to be 
challenging in several cases. One of the reasons was 
the high incidence of autoimmune thyroid disease: 
elevated TPOAbs or TgAbs (18%), decreased thyroid 
echogenicity (12%), and increased thyroid vascularisa-
tion (14%). Taking into account that TRAb assays based 
on porcine TSH receptor have slightly lower sensitivity 
compared to TRAb — human assays [44], and the fact 
that a few (up to 7%) of patients with Graves’ disease 
remain TRAb negative even when 3rd generation TSH-
receptor antibody assays are used [45, 46], a small 
degree of uncertainty towards the underlying cause 
of hyperthyroidism accompanied some of the cases. 
In fact, one of our patients with gestational thyrotox-
icosis, being TRAb negative and TPOAb positive during 
pregnancy, developed severe Graves’ hyperthyroidism 
with high serum TRAbs in the postpartum period. 
Further diagnostic difficulties resulted from long-term 
persistence of TSH suppression (even until the 38th 
WG, mean 20th WG) and high incidence of nodular 
goitre (32%), which could lead to misdiagnosis of toxic 
nodular goitre in some patients. In fact, only a sponta-
neous normalisation of TSH in the postpartum period 
allowed the differentiation between toxic nodular goitre 
and gestational hyperthyroidism in two women with 
nodular goitre and prolonged suppression of TSH. The 
abovementioned premises and high incidence of hy-
peremesis gravidarum contributed to a quite frequent 
use of ATD in this group (34%). Short-term ATD therapy 
limited to the 1st trimester resulted in normal foetal US 
performance observed in the 18th–23rd and the 30th–33rd 
WG. In view of the reports on the possible influence 
of maternal thyroid dysfunction during pregnancy on 
the pituitary-thyroid axis function in offspring [47], 
we compared the distribution of TSH levels obtained 
in dried-spot tests in children delivered by mothers 
with gestational hyperthyroidism and in the controls. 
No significant differences were noted between the two 
groups. However, this observation must be treated with 
caution, because the dried-spot test is not sensitive 
enough to estimate very low TSH levels.
Forty two of our patients had Graves’ disease. This 
group included 16 individuals with a past history of 
hyperthyroidism; remission was achieved in 14 (87.5%) 
of these patients with either surgery (25%) or radioio-
dine therapy (62.5%). Women with past and current 
Graves’ hyperthyroidism did not differ significantly in 
terms of TRAb positivity (31% v. 42%) and TRAb serum 
concentrations (3.09 ± 8.07 v. 7.01 ± 11.2 IU/mL). These 
results were influenced mainly by the high percentage 
of women treated previously with radioiodine; it has 
long been recognised that 131I therapy results in a rise in 
thyroid autoantibodies, with a peak at 3–6 months and 
elevated levels sustained for several years [48, 49]. How-
ever, in the group with past Graves’ hyperthyroidism, 
the maternal and child outcome was disturbed in only 
one extraordinary case, in which hyperthyroidism with 
high serum TRAbs relapsed in the 3rd trimester, after 
11 years of history of postoperative hypothyroidism.
Among 42 women with Graves’ disease, there 
were 26 patients with current hyperthyroidism. In 
this group, 61.5% of women became pregnant while 
on ATD therapy, lasting 13.6 months on average (up to 
38 months in some cases). This observation is surprising 
as the Polish Endocrine Society does not recommend 
conceiving during a course of anti-thyroid medication 
[27]. The guidelines of the American Thyroid Society 
(ATA) [26] strongly recommend pre-pregnancy counsel-
ling for all patients with hyperthyroidism or a history of 
hyperthyroidism, and reaching euthyroid state prior to 
conception. According to ATA guidelines, hyperthyroid 
women should be offered ablative (131-I, surgery) or 
medical therapy, and conception is advised when the 
disease is controlled. Our results demonstrating higher 
incidences of foetal and neonatal thyroid dysfunction 
Figure 3. Comparison of the distributions of TSH levels obtained 
in dried-spot tests in the neonates born to mothers with gestational 
hyperthyroidism and in the control group
Group A — controls (n = 68), group B — studied group (n = 34)
Rycina 3. Porównanie rozkładu TSH badanego testem bibułowym 
u dzieci pochodzących od matek z tyreotoksykozą ciężarnych z 
grupą kontrolną 
Grupa A — kontrolna (n = 68), grupa B — badani (n = 34)
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in hyperthyroid mothers treated with ATD than in 
mothers who reached a remission after surgical or 
radioiodine treatment (31% and 11.5 % vs. 6% and 
6%, respectively; p < 0.001) provide the rationale for 
offering ablative therapy prior to conception. Surgery 
should be elective in women with large goitres or high 
TRAb levels, while 131-I therapy seems optimal in other 
cases. Generally, 21% of children from the group of 
women with current or past Graves’ hyperthyroidism 
demonstrated thyroid dysfunction during their foetal 
life, and 7% showed abnormal thyroid function during 
the neonatal period. The incidence of foetal thyroid 
dysfunction documented in our study was higher than 
the commonly reported 1–5% [3,27], but still consist-
ent with the 19–25% documented by the authors who 
have performed US foetal monitoring [33, 35, 50]. The 
observed incidence of neonatal thyroid dysfunction was 
similar to the previously reported 1-16.5% [3, 25, 51, 52]. 
Our study confirmed the high sensitivity and value of 
foetal US monitoring in mothers affected by Graves’ 
disease. Abnormal thyroid sonogram, namely, goitre 
with decreased echogenicity and increased vascularisa-
tion, turned out to be the most sensitive symptom of 
foetal thyroid dysfunction. It is of note that the same US 
abnormalities were observed in 85% of adult patients 
with Graves’ disease [53]. We used the established 
foetal thyroid nomograms for the Polish population 
[31] in diagnosing foetal goitre. The nomograms differ 
slightly from those reported by other authors [30, 54, 55], 
probably due to mild iodine deficiency still observed 
in the population of Polish pregnant women [39, 56]. 
Decreased echogenicity and increased central blood 
flow in foetal thyroid were observed in each case of 
foetal hyperthyroidism. The size of foetal thyroid was 
within the upper normal limit (between the 90th and 95th 
percentiles) in 50% of cases, and thyroid enlargement 
was documented in the other 50%. Plausibly, intensive 
central blood flow in foetal thyroid was the earliest sign 
of foetal hyperthyroidism, preceding enlargement of 
the gland, but this observation should be confirmed 
in a larger study. Foetal goitre with various patterns 
of vascularisation, such as lack of increased blood flow 
(in two out of five patients, 40%), increased peripheral 
blood flow (n = 2, 40%) or increased central blood 
flow (n = 1, 20%), was observed in each case of foetal 
hypothyroidism. According to previous observations 
[26,35], foetal goitre seems to be the earliest and most 
accurate sign of foetal thyroid dysfunction resulting 
from maternal thyroid disease. Its sensitivity for foetal 
thyroid dysfunction was assessed at 92%, specificity at 
100%, and PPV and NPV at 100% and 98%, respectively 
[35]. Increased central blood flow was observed in all 
cases of foetal hyperthyroidism and in 29% of cases 
of foetal hypothyroidism [35]. Goitre with increased 
peripheral blood flow (57%) was the most characteris-
tic US indication of foetal hypothyroidism. Abnormal 
foetal thyroid performance was the only US sign of 
foetal thyroid dysfunction in our material. According to 
other authors [35, 57], abnormal bone maturation and 
heart rate are both late and uncommon symptoms of 
foetal thyroid dysfunction, present in 36% and 14% of 
cases, respectively. 
The lack of bone and heart abnormalities in the 
offspring of our patients might result from early recog-
nition of foetal thyroid dysfunction. The high level of 
TRAbs, at least five-fold higher than the upper normal 
limit, and the presence of hyperthyroidism in the 3rd 
trimester, were the most characteristic maternal pa-
rameters that predisposed for foetal hyperthyroidism. 
The highly elevated maternal TRAbs were also noted 
in four (9.5%) cases of maternal Graves’ disease that 
lacked maternal or foetal thyroid disturbances. This was 
probably associated with the well-known phenomenon 
of switching TSH receptor antibodies from stimulating 
to inhibiting activity [58, 59]. This finding points to the 
need to assess biological activity of the TSH receptor 
antibodies in some cases, especially in women who 
underwent ablative therapy. There is no correlation 
between maternal thyroid function and maternal serum 
TRAb concentration in such cases, and the impact of 
maternal TRAbs on the foetus is uncertain. Our opinion 
is consistent with other authors [60], who postulate per-
forming TRAb and complementary thyroid stimulating 
immunoglobulin tests. Similar to previous studies [35], 
maternal ATD therapy, and low maternal serum TRAb 
and fT4 levels turned out to be the risk factors for foetal 
hypothyroidism in our material.
We are well aware that the lack of a uniform assess-
ment of neonatal status by TSH, fT4 and fT3 measure-
ments in cord blood constitutes a potential limitation 
of our study. Unfortunately, some of our patients de-
livered outside our unit and therefore neonatal thyroid 
function was assessed between the 1st and 3rd days of 
life. TSH concentration obtained in dried-blood spot 
testing protocols, performed after the first 48 hours of 
life as a screening for congenital hypothyroidism, was 
the only information about the neonatal thyroid status 
in some cases. 
Nevertheless, our study did confirm the great value 
of foetal ultrasound monitoring in maternal Graves’ 
disease with high serum TRAb levels and ATD therapy. 
This observation also certifies the value of our previ-
ously established age-dependent nomograms of foetal 
thyroid. Our experience emphasises the need for close 
interdisciplinary collaboration of endocrinologists, 
obstetricians, neonatologists and paediatricians in the 
management of pregnancies complicated by maternal 
Graves’ disease.
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Conclusions
1. In cases of maternal Graves’ disease, foetal thyroid 
dysfunction occurs more often than has been com-
monly assumed.
2. Foetal thyroid ultrasonography is a valuable tool 
in the early diagnosis and monitoring of the foetal 
thyroid status when a pregnancy is complicated by 
maternal Graves’ disease.
3. The evaluation of biological activity of maternal 
TRAbs may be helpful in prenatal diagnosis in some 
cases, especially after previous ablative thyroid 
therapy.
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